Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05343793 · ClinicalTrials.gov registry record · NA
Stagewise Implementation-To-Target- Medications for Addiction Treatment (SITT-MAT)
A NA study of Addiction, Opioid, sponsored by Stanford University.
- Active
- Registry status
- NA
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT05343793: Active NA study of Addiction, Opioid, sponsored by Stanford University.
NCT05343793 is a NA study of Addiction, Opioid that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 47 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05343793, a NA study of Addiction, Opioid, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to expand access to medications for opioid use disorder (MOUD) in specialty addiction programs in Washington State. Sixty-four addiction treatment programs will participate in an adaptive implementation strategy trial that uses a stagewise implementation-to-target (stepped "care" type) approach whereby organizations engage in increasingly intensive implementation strategies as needed. Organizations are moved to a follow-up/sustainment arm once they have met the implementation targets described below. The design also includes an external comparator arm, which consists of 510 addiction treatment programs that are not participating in the study and will mimic as study controls. The sequence of implementation strategies are: 1. Enhanced Monitoring and Feedback 2. NIATx/MAT Academy 3. Randomization to either NIATx Internal Facilitation or NIATx External Facilitation 4. Assignment to NIATx External Facilitation if outcome targets are not achieved in the NIATx Internal Facilitation arm Implementation targets are: 1. Reach - At least 75% of patients with opioid use disorder (OUD) receiving MOUD for three consecutive months 2. Adoption - At least 1 integrated MOUD prescriber actively prescribing MOUD 3. Implementation - a total score ≥ 4 on the Integrating Medications for Addiction Treatment (IMAT) Index. Contextual moderators and mediators of performance on target outcomes as a function of the implementation strategy step will be examined, as will the costs associated with participation in the sequence of implementation strategies.
Primary Outcome
The proportion of program patients with OUD and receiving MOUD (buprenorphine, naltrexone) within the index quarter.
Conditions Studied
Interventions
- OTHER Enhanced Monitoring and Feedback (EMF)
- OTHER NIATx/MAT Academy
- OTHER NIATx-Internal Facilitation (NIATx-IF)
- OTHER NIATx-External Facilitation (NIATx-EF)
Study Locations (1)
Washington
- Washington State Healthcare Authority - Olympia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What the registry record for NCT05343793 still lists
NCT05343793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Addiction, Opioid appearing as the primary indexed condition, and to 4 interventions - of which Enhanced Monitoring and Feedback (EMF) is the first listed.
NCT05343793 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT05343793 about?
NCT05343793 is a clinical study titled "Stagewise Implementation-To-Target- Medications for Addiction Treatment (SITT-MAT)". The purpose of this study is to expand access to medications for opioid use disorder (MOUD) in specialty addiction programs in Washington State. Sixty-four addiction treatment programs will participate in an adaptive implementation strategy trial that uses a stagewise implementation-to-target (stepp...
What is the current status of trial NCT05343793?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 47 participants. The study started on 2022-03-14. Estimated completion is 2026-06-30.
What conditions does trial NCT05343793 study?
This clinical trial studies the following conditions: Addiction, Opioid.
What interventions are being tested in trial NCT05343793?
The interventions under investigation include: Enhanced Monitoring and Feedback (EMF) (OTHER), NIATx/MAT Academy (OTHER), NIATx-Internal Facilitation (NIATx-IF) (OTHER), NIATx-External Facilitation (NIATx-EF) (OTHER).
Who is sponsoring clinical trial NCT05343793?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05343793 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Addiction, Opioid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05343793's enrollment target sits among peer trials
47 1400th of 2000 higher than 599 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI